- Home
- KURA
KURA
Kura Oncology Inc.
as 11-15-2024 4:00pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $29.83 | AVG Volume (30 days): | 821.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.06 - $24.17 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
Associated Press Finance
9 days ago
Kura Oncology: Q3 Earnings Snapshot
GlobeNewswire
9 days ago
Kura Oncology Reports Third Quarter 2024 Financial Results
GlobeNewswire
11 days ago
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
GlobeNewswire
17 days ago
Kura Oncology to Report Third Quarter 2024 Financial Results
MT Newswires
23 days ago
UBS Initiates Kura Oncology With Buy Rating, $27 Price Target
GlobeNewswire
24 days ago
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire
25 days ago
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.